Recordati Industria Chimica e Farmaceutica SpA
MIL:REC

Watchlist Manager
Recordati Industria Chimica e Farmaceutica SpA Logo
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
Watchlist
Price: 50.5 EUR 0.2% Market Closed
Market Cap: 10.4B EUR
Have any thoughts about
Recordati Industria Chimica e Farmaceutica SpA?
Write Note

Recordati Industria Chimica e Farmaceutica SpA
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Recordati Industria Chimica e Farmaceutica SpA
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
Total Current Assets
€1.2B
CAGR 3-Years
9%
CAGR 5-Years
1%
CAGR 10-Years
8%
Newron Pharmaceuticals SpA
SIX:NWRN
Total Current Assets
€20.1m
CAGR 3-Years
-10%
CAGR 5-Years
-20%
CAGR 10-Years
N/A
P
Pierrel SpA
MIL:PRL
Total Current Assets
€17.6m
CAGR 3-Years
10%
CAGR 5-Years
18%
CAGR 10-Years
-1%
Friulchem SpA
MIL:FCM
Total Current Assets
€16.7m
CAGR 3-Years
23%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Shedir Pharma Srl Unipersonale
MIL:SHE
Total Current Assets
€41.9m
CAGR 3-Years
1%
CAGR 5-Years
6%
CAGR 10-Years
N/A
No Stocks Found

Recordati Industria Chimica e Farmaceutica SpA
Glance View

Market Cap
10.4B EUR
Industry
Pharmaceuticals

Nestled within the vibrant landscape of the Italian pharmaceutical industry, Recordati Industria Chimica e Farmaceutica SpA has carved a distinct identity over its nearly century-long journey. Founded in 1926 by Giovanni Recordati, the company has evolved from a small chemical laboratory into one of Europe's prominent players in pharmaceuticals. The heart of Recordati's operations lies in its robust portfolio, which spans pharmaceuticals, rare disease treatments, and consumer health products. With a commitment to innovation and diligent R&D efforts, Recordati continuously develops both proprietary drugs and generic medicines, ensuring a diverse revenue stream. Aiming to address crucial health challenges, the company has strategically expanded its rare disease segment, exploring niche markets with high unmet medical needs. Recordati's business model is a sophisticated blend of internal development, strategic acquisitions, and partnerships. The company's success largely hinges on its ability to identify and integrate complementary businesses, enhancing its global footprint. Through a network covering Western Europe, Central and Eastern Europe, as well as North America and emerging markets, Recordati not only distributes its own line of medications but also collaborates with other pharmaceutical entities to commercialize their products. This strategic expansion, coupled with a proactive approach to fostering market-specific adaptations, supports a steady flow of revenue. Revenue sustainability is further bolstered by a responsive supply chain and targeted marketing strategies that strengthen Recordati's competitive stance in the pharmaceutical sector worldwide.

REC Intrinsic Value
58.09 EUR
Undervaluation 13%
Intrinsic Value
Price

See Also

What is Recordati Industria Chimica e Farmaceutica SpA's Total Current Assets?
Total Current Assets
1.2B EUR

Based on the financial report for Sep 30, 2024, Recordati Industria Chimica e Farmaceutica SpA's Total Current Assets amounts to 1.2B EUR.

What is Recordati Industria Chimica e Farmaceutica SpA's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
8%

Over the last year, the Total Current Assets growth was 2%. The average annual Total Current Assets growth rates for Recordati Industria Chimica e Farmaceutica SpA have been 9% over the past three years , 1% over the past five years , and 8% over the past ten years .

Back to Top